Publication | Closed Access
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
73
Citations
0
References
2012
Year
Cancer ManagementPathologyPharmacotherapyGenitourinary CancerCancer Cell BiologyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyChemotherapy-naive PatientsFinal TextMedicineAsco Daily NewsCancer TreatmentProstatic DiseasePharmacologyInterim AnalysisUrologyAbiraterone AcetateOncology
LBA4518 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.